Eiger BioPharmaceuticals, Inc. (EIGR) News
Filter EIGR News Items
EIGR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EIGR News Highlights
- EIGR's 30 day story count now stands at 2.
- Over the past 10 days, the trend for EIGR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest EIGR News From Around the Web
Below are the latest news stories about Eiger BioPharmaceuticals Inc that investors may wish to consider to help them evaluate EIGR as an investment opportunity.
Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, March 10, 2022 at 4:30 PM ET to discuss its fourth quarter and full year 2021 financial results and provide a business update. |
What Kind Of Investors Own Most Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)?If you want to know who really controls Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ), then you'll have to look at the... |
Pflug Koory, LLC Buys Vertex Pharmaceuticals Inc, Amgen Inc, NVIDIA Corp, Sells Adobe Inc, ...Investment company Pflug Koory, LLC (Current Portfolio) buys Vertex Pharmaceuticals Inc, Amgen Inc, NVIDIA Corp, Altria Group Inc, Wynn Resorts, sells Adobe Inc, Domtar Corp, AT&T Inc, BTC BlackRock Short Maturity Bond ETF, American States Water Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Pflug Koory, LLC. |
Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and MilestonesEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today provided the company's outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones. |
Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual ConferenceEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that David Cory, President and CEO, will provide a corporate update at the H.C. Wainwright BioConnect 2022 Virtual Conference. |
Those who invested in Sempra (NYSE:SRE) five years ago are up 52%The main point of investing for the long term is to make money. But more than that, you probably want to see it rise... |
Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) InfectionPALO ALTO, Calif., Dec. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious |
Sempra Announces Agreement To Sell 10% Interest In Sempra Infrastructure PartnersSempra (NYSE: SRE) (BMV: SRE) announced today it has entered into a definitive agreement to sell a non-controlling 10% interest in Sempra Infrastructure Partners (Sempra Infrastructure) to a subsidiary of the Abu Dhabi Investment Authority (ADIA) for $1.785 billion in cash, subject to customary closing adjustments. |
Sempra Named Top Energy Company on The Wall Street Journal's Management Top 250 RankingSempra (NYSE: SRE) (BMV: SRE) today announced it is the highest-ranked energy company on the Wall Street Journal's Management Top 250 ranking for 2021, one of the most prestigious ranking efforts dedicated to measuring corporate effectiveness. This is the third time the company has been named to the Management Top 250, a list which began in 2017. |
Is Eiger BioPharmaceuticals (NASDAQ:EIGR) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says... |